Literature DB >> 24304215

False activation of the cardiac catheterization laboratory for primary PCI.

Geoffery D Barnes1, Alexander Katz, Jeffrey S Desmond, Steven L Kronick, Jamie Beach, Stanley J Chetcuti, Eric R Bates, Hitinder S Gurm.   

Abstract

OBJECTIVES: We sought to evaluate trends in door-to-balloon (D2B) times and false activation rates for the cardiac catheterization laboratory (CCL) in patients presenting to the emergency department (ED) with acute ST-elevation myocardial infarction (STEMI). In patients with STEMI, national efforts have focused on reducing D2B times for primary percutaneous coronary intervention (P-PCI). This emphasis on time-to-treatment may increase the rate of false CCL activations and unnecessary healthcare utilization. STUDY
DESIGN: Retrospective quality improvement chart review.
METHODS: We examined all emergent CCL activations for P-PCI between 2007 and 2011 at the University of Michigan Hospital. False activation was defined as emergent CCL activation when the patient did not require CCL care or emergent cardiology evaluation in the ED. Pre-hospital or ED false activation rates and mean D2B time were retrospectively determined by chart review.
RESULTS: The CCL was activated 717 times for suspected STEMI. The number of CCL activations increased from 96 in 2007 to 190 in 2011. False CCL activations accounted for 28% of all prehospital and 29% of all ED activations. The false activation rate increased from 15% of all cases in 2007 to 40% of all cases in 2011. The median D2B time decreased from 67 minutes in 2007 to 55 minutes in 2011.
CONCLUSIONS: Over a 5-year period with a strong emphasis on reducing D2B times, there has been an increased CCL false activation rate for P-PCI.

Entities:  

Mesh:

Year:  2013        PMID: 24304215

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  6 in total

Review 1.  Oxygen therapy for acute myocardial infarction.

Authors:  Juan B Cabello; Amanda Burls; José I Emparanza; Susan E Bayliss; Tom Quinn
Journal:  Cochrane Database Syst Rev       Date:  2016-12-19

2.  Aggressive Measures to Decrease "Door to Balloon" Time and Incidence of Unnecessary Cardiac Catheterization: Potential Risks and Role of Quality Improvement.

Authors:  Zaher Fanari; Niksad Abraham; Paul Kolm; Jennifer Doorey; Angela Herman; Angela Hoban; Vivek Reddy; Sumaya Hammami; Jennifer Leonovich; Ehsanur Rahman; William S Weintraub; Andrew J Doorey
Journal:  Mayo Clin Proc       Date:  2015-11-06       Impact factor: 7.616

3.  Decade-long trends in the timeliness of receipt of a primary percutaneous coronary intervention.

Authors:  Han-Yang Chen; Joel M Gore; Kate L Lapane; Jorge Yarzebski; Sharina D Person; Catarina I Kiefe; Robert J Goldberg
Journal:  Clin Epidemiol       Date:  2016-06-06       Impact factor: 4.790

4.  Risk score to predict false-positive ST-segment elevation myocardial infarction in the emergency department: a retrospective analysis.

Authors:  Ji Hoon Kim; Yun Ho Roh; Yoo Seok Park; Joon Min Park; Bo Young Joung; In Cheol Park; Sung Phil Chung; Min Joung Kim
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2017-06-30       Impact factor: 2.953

5.  False activation of the cardiac catheterization laboratory: The price to pay for shorter treatment delay.

Authors:  George Degheim; Abeer Berry; Marcel Zughaib
Journal:  JRSM Cardiovasc Dis       Date:  2019-04-08

6.  Prehospital Activation of Hospital Resources (PreAct) ST-Segment-Elevation Myocardial Infarction (STEMI): A Standardized Approach to Prehospital Activation and Direct to the Catheterization Laboratory for STEMI Recommendations From the American Heart Association's Mission: Lifeline Program.

Authors:  Michael C Kontos; Michael R Gunderson; Jessica K Zegre-Hemsey; David C Lange; William J French; Timothy D Henry; James J McCarthy; Claire Corbett; Alice K Jacobs; James G Jollis; Steven V Manoukian; Robert E Suter; David T Travis; J Lee Garvey
Journal:  J Am Heart Assoc       Date:  2020-01-20       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.